SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves quarterly results beat expectations and the company raised its outlook, with a large revenue backlog and expected customer prepayments drawing attention. Bulls say strong AI-compute demand and contract-backed funding ease financing concerns, while bears remain focused on heavy debt, interest costs and capital spending; the share reaction has been muted despite the upbeat results.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy dominates discussion, with traders parsing managements comments on labeling and launch readiness as possible signs of approval. Optimism about the drugs prospects and cardiac data is countered by concerns that approval is uncertain and the decision could bring a sharp downside; the earnings report and a dispute with NS Pharma are secondary topics.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and earnings call are driving attention, with traders focused on Samsung licensing revenue, improving profitability and margins, and expected recurring Micron payments and stronger product sales ahead. Bullish reactions emphasize the stronger financial outlook, while skeptics point to lower quarter-over-quarter product sales and the lack of confirmed SK Hynix or Nasdaq updates; speculation about a Hynix deal remains unconfirmed.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigettis Q3 results missed expectations, prompting concern about weak revenue, ongoing losses, and a long path to commercialization. Bears question the valuation of a pre-revenue quantum-computing business, while bulls argue that technical progress and the sectors long-term potential matter more than current financials.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias selloff is focused on the board investigation into CEO Jensen Huangs acknowledged affair with an executive alleged to have ties to Chinese intelligence, and speculation about possible disclosure or export-control risks; the claims of compromised company secrets remain unsubstantiated. Traders are divided between viewing the controversy and potential leadership risk as grounds for further downside and treating the decline as a buying opportunity because they believe Nvidias AI business remains strong.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPaths quarterly results are driving attention: revenue came in below expectations, while earnings per share beat and the company reported a record backlog and improved gross margins. Traders are split between viewing backlog growth and supply-chain recovery as evidence of strong execution and worrying that delayed deliveries and the revenue miss undermine the growth story.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius quarterly report is driving attention: revenue growth and raised full-year revenue guidance were offset by an earnings-per-share miss and weaker-than-expected EBITDA guidance, prompting a sharp selloff. Traders are divided between viewing the drop as an overreaction to the narrow miss and worrying about profitability, cash burn, and dilution risk.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costcos declared special cash dividend and renewed stock-buyback authorization are driving attention, with traders welcoming the large payout while noting the share price adjusts for the dividend on the ex-date. The reaction is broadly upbeat, though some remain focused on Costcos premium valuation and caution that the dividend is not free money.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kuras Q3 results and call have focused attention on growing KOMZIFTI use, with traders highlighting higher prescriptions and patient starts and praising managements defense of the drugs position against J&J competition. The reaction is broadly encouraged by the launch momentum, though some traders are concerned about a stock issuance and debate how competitive J&Js data may prove.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNavs quarterly results are drawing attention after an earnings-per-share beat and year-over-year revenue growth. Traders are divided on whether the results matter: some welcome the improvement, while others say the stocks longer-term case still hinges on FCC action on its proposed spectrum reconfiguration.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ABVX has identified α4β7 as its leading candidate mechanism for an Obefazimod combination, they will confirm their molecule for combo before JPM in Jan 27.  
 
Following companies have developed molecules that inhibit α4β7 
 
$LLY  Zotemtegrast (MORF-057 / LY4268989) 
$GILD Emvistegrast (GS-1427) — an oral, once-daily α4β7 inhibitor 
$ABBV ABBV-382 — an anti-α4β7 monoclonal antibody 
$SNY HXN-1002 — a bispecific antibody targeting both TL1A and α4β7. 
 
For a company that already owns an α4β7 molecule, acquiring Abivax could potentially create a combination franchise with two complementary mechanisms. 
 
Lilly is particularly interesting here. It already owns an oral α4β7 inhibitor and is actively testing it in combination with mirikizumab. Adding obefazimod could give Lilly another potential combination option, with a different mechanism from both drugs.

BioSwings™

Rainer Zufall

GARY MOR

Jeff Galewood (JMG)

SJTD

Jim Williams

GaryBusey1

StockTwits Web

Abivax - ADR

Lilly(Eli) & Co

Gilead Sciences, Inc.

Abbvie Inc

Sanofi-Aventis

 has identified α4β7 as its leading candidate mechanism for an Obefazimod combination, they will confirm their molecule for combo before JPM in Jan 27.  
 
Following companies have developed molecules that inhibit α4β7 
 


 Emvistegrast (GS-1427) — an oral, once-daily α4β7 inhibitor 


 ABBV-382 — an anti-α4β7 monoclonal antibody 


 HXN-1002 — a bispecific antibody targeting both TL1A and α4β7. 
 
For a company that already owns an α4β7 molecule, acquiring Abivax could potentially create a combination franchise with two complementary mechanisms. 
 
Lilly is particularly interesting here. It already owns an oral α4β7 inhibitor and is actively testing it in combination with mirikizumab. Adding obefazimod could give Lilly another potential combination option, with a different mechanism from both drugs.

Neeraj Jain

$ABVX is running preclinical studies to identify a molecule that could be combined with obefazimod. Management intends to select a mechanism by the end of 2026 and issue a more detailed update in early Jan 2027, before JPM.  
I wonder whether this study is to show $LLY why they should up the offer and meet the ask.

 is running preclinical studies to identify a molecule that could be combined with obefazimod. Management intends to select a mechanism by the end of 2026 and issue a more detailed update in early Jan 2027, before JPM.  
I wonder whether this study is to show 

 why they should up the offer and meet the ask.